176 related articles for article (PubMed ID: 38252191)
1. Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding.
Fele-Paranj A; Saboury B; Uribe C; Rahmim A
EJNMMI Radiopharm Chem; 2024 Jan; 9(1):6. PubMed ID: 38252191
[TBL] [Abstract][Full Text] [Related]
2. Correction: Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding.
Fele-Paranj A; Saboury B; Uribe C; Rahmim A
EJNMMI Radiopharm Chem; 2024 Mar; 9(1):22. PubMed ID: 38504056
[No Abstract] [Full Text] [Related]
3. Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to
Piranfar A; Soltani M; Kashkooli FM; Uribe CF; Rahmim A
Comput Methods Programs Biomed; 2024 Mar; 245():108004. PubMed ID: 38215660
[TBL] [Abstract][Full Text] [Related]
4. Theranostic digital twins for personalized radiopharmaceutical therapies: Reimagining theranostics
Rahmim A; Brosch-Lenz J; Fele-Paranj A; Yousefirizi F; Soltani M; Uribe C; Saboury B
Front Oncol; 2022; 12():1062592. PubMed ID: 36591527
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients.
Kovar L; Weber A; Zemlin M; Kohl Y; Bals R; Meibohm B; Selzer D; Lehr T
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32977559
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
[TBL] [Abstract][Full Text] [Related]
7. Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review.
Siebinga H; de Wit-van der Veen BJ; Stokkel MDM; Huitema ADR; Hendrikx JJMA
Theranostics; 2022; 12(18):7804-7820. PubMed ID: 36451855
[No Abstract] [Full Text] [Related]
8.
Isoherranen N
Drug Metab Dispos; 2024 Feb; ():. PubMed ID: 38326033
[TBL] [Abstract][Full Text] [Related]
9. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
10. Predicting In Vivo Target Occupancy (TO) Profiles via Physiologically Based Pharmacokinetic-TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions.
Lee W; Kim MS; Kim J; Aoki Y; Sugiyama Y
Drug Metab Dispos; 2023 Sep; 51(9):1145-1156. PubMed ID: 36914276
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.
Laplanche R; Meno-Tetang GM; Kawai R
J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):373-400. PubMed ID: 17431753
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans.
Ganti A; Yu S; Sharpnack D; Ingalla E; De Bruyn T
Biopharm Drug Dispos; 2023 Aug; 44(4):301-314. PubMed ID: 37102506
[TBL] [Abstract][Full Text] [Related]
14. Toxicokinetic modeling and its applications in chemical risk assessment.
Andersen ME
Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach.
Cheng YH; He C; Riviere JE; Monteiro-Riviere NA; Lin Z
ACS Nano; 2020 Mar; 14(3):3075-3095. PubMed ID: 32078303
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modeling to Simulate CYP3A4-Mediated Drug-Drug Interactions for Pyrotinib.
Ni L; Zheng L; Liu Y; Xu W; Zhao Y; Wang L; Zhang Q; Hu W; Chen X
Adv Ther; 2023 Oct; 40(10):4310-4320. PubMed ID: 37455292
[TBL] [Abstract][Full Text] [Related]
18. Current Status of Radiopharmaceutical Therapy.
St James S; Bednarz B; Benedict S; Buchsbaum JC; Dewaraja Y; Frey E; Hobbs R; Grudzinski J; Roncali E; Sgouros G; Capala J; Xiao Y
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):891-901. PubMed ID: 32805300
[TBL] [Abstract][Full Text] [Related]
19. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
Chen Y; Ma F; Lu T; Budha N; Jin JY; Kenny JR; Wong H; Hop CE; Mao J
Clin Pharmacokinet; 2016 Jun; 55(6):735-49. PubMed ID: 26692192
[TBL] [Abstract][Full Text] [Related]
20. A Comparative Evaluation of Desoximetasone Cream and Ointment Formulations Using Experiments and In Silico Modeling.
Matharoo NS; Garimella HT; German C; Przekwas AJ; Michniak-Kohn B
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
